Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting

American Health and Drug Benefits

Volumn 7, Issue 7, 2014, Pages 376-384

  Armbruster, Anastasia L ^a   Buehler, Katie S ^a   Min, Sun H ^b   Riley, Margaret ^c   Daly, Michael W ^d  

^a Department of Pharmacy Practice St Louis College of Pharmacy   (United States)

^b Walgreens Co   (United States)

^c INDIANA UNIVERSITY HEALTH   (United States)

^d Mail Code S106 6465   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CARVEDILOL; CLARITHROMYCIN; CLOPIDOGREL; CYCLOSPORIN; DABIGATRAN; DALTEPARIN; DICLOFENAC; DIPYRIDAMOLE; DRONEDARONE; ENOXAPARIN; FONDAPARINUX; HEMOGLOBIN; HEPARIN; IBUPROFEN; ITRACONAZOLE; KETOROLAC; NAPROXEN; PRASUGREL; PROPRANOLOL; RANOLAZINE; TAMOXIFEN; TICAGRELOR; TRAZODONE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMMUNITY HOSPITAL; DRUG MEGADOSE; ELECTRONIC MEDICAL RECORD; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84908614203     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095-1106
2. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med. 2000;109:481-488
3. Pradaxa (dabigatran etexilate mesylate) capsules [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; September 2014
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al ; for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. Erratum in: N Engl J Med. 2010;363:1875-1876
5. US Food and Drug Administration. FDA drug safety communication: update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran). November 2, 2012. Updated August 14, 2014. www.fda.gov/Drugs/DrugSafety/ ucm326580.htm. Accessed June 30, 2014
6. US Food and Drug Administration. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. May 13, 2014. www.fda.gov/Drugs/DrugSafety/ucm396470.htm. Accessed September 19, 2014
7. Schulman S, Kearon C, Kakkar AK, et al for the RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352
8. Schulman S, Kakkar AK, Goldhaber SZ, et al ; for the RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764-772
9. Xarelto (rivaroxaban) tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; March 2014
10. Patel MR, Mahaffey KW, Garg J, et al ; for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891
11. Bauersachs R, Berkowitz SD, Brenner B, et al ; for the EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-2510
12. Büller HR, Prins MH, Lensing AW, et al ; for the EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-1297
13. Eliquis (apixaban) tablets [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; August 2014
14. Granger CB, Alexander JH, McMurray JJ, et al ; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992
15. Connolly SJ, Eikelboom J, Joyner C, et al ; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817
16. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Mar 28 [Epub ahead of print]
17. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285-295
18. Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy. 2011;31:1175-1191
19. Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013;47:1635-1640
20. Chin PKL, Vella-Brincat JWA, Walker SL, et al. Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Int Med J. 2013;43:778-783
21. The Joint Commission. National Patient Safety Goals effective January 1, 2014: hospital accreditation program 2013. www.jointcommission.org/assets/1/6/HAP_ NPSG_Chapter_2014.pdf. Accessed June 18, 2014
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41
23. Tedders KM, Lucey MF, Edwin SB. Evaluation of pharmacist-managed dabigatran in an inpatient setting. Ann Pharmacother. 2013;47:1649-1653
24. Eikelboom JW, Connolly SJ, Brueckmann M, et al for the RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-1214
25. Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012;43:881-883.